Trevena Priced, Nasdaq: TRVN
Clinical-stage biotech developing treatments for pain and acute heart failure.
Industry: Health Care
First Day Return: -7.1%
TRVN
Clinical-stage biotech developing treatments for pain and acute heart failure.
| IPO Data | |
|---|---|
| IPO Date | 01/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | King of Prussia, PA, United States |
| Founded | 2007 |
| Employees at IPO | 31 |
| Website www.trevenainc.com | |
Trevena (TRVN) Performance
